Investing.com -- MoonLake Immunotherapeutics (NASDAQ:MLTX) shares rose 6.6% in premarket trading Monday following positive topline results from its Phase 2 S-OLARIS trial of sonelokimab in axial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results